Papel del estrés oxidativo en la esquizofrenia

Autores/as

  • Maria Clara Soto Bernardini Universidad de Costa Rica
  • Henriette Raventós Vorst Universidad de Costa Rica

DOI:

https://doi.org/10.51481/amc.v50i4.3

Palabras clave:

estrés oxidativo, esquizofrenia, oxi-radicales, sistema de defensa antioxidante

Resumen

La esquizofrenia es una enfermedad mental severa que se presenta en alrededor del 1% de la población mundial. Para que se manifieste son necesarios tanto factores genéticos como ambientales, por lo que el genotipo de riesgo no conlleva al desarrollo de la enfermedad sino a una mayor susceptibilidad de presentarla. Existe evidencia de que el balance entre la producción de radicales libres y el sistema de defensa antioxidante está alterado en pacientes con esquizofrenia. Sin embargo, no se sabe con certeza si la producción de RLs tiene un papel causal en el desarrollo de la enfermedad o es producido durante el curso de la enfermedad, o por el uso de neurolépticos. En este artículo se revisa la evidencia de la participación de estas sustancias en el desarrollo dela enfermedad.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Sawa N, Snyder S. Schizophrenia: diverse approaches to complex disease. Science 2002; 296: 692-695.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4ed., Washington DC: Am Psychiatr Assoc, 1994.

McGuffin P, Owen M, Farmer A. Genetic basis of schizophrenia. Lancet 1995; 346: 678-682.

Cardno A, Gottesman I. Twin studies of schizophrenia: from bowand-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000; 97: 12-17.

Leask SJ. Enviromental influences in schizophrenia: the known and unknown. Adv Psych Treat. 2004;10:323-330.

Pacheco A, Raventós H. Genética de la esquizofrenia: avances en el estudio de genes candidatos. Rev Biol Trop 2004; 52: 1-7.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit T. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-1213.

Owen M, Craddock N, O'Donovan M. Schizophrenia: genes at last? Trends Genet 2005; 21: 518-525.

Bardner J, Gershon E. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molec Psychiatry 2002; 7: 405411.

Lewis C, Levinson D, Wise L, DeLisi L, Straub R, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003; 73: 34-48.

Mahadik S, Scheffer R. Oxidative injury and potential use of antioxidants in schizophrenia. Prostagland, Leukotr and Essenc Fat Ac 1996; 55: 45-54.

Mahadik S, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996; 19: 1-17.

Mary J, Vougier S, Picot C, Perichon M, Petropoulos I, Friguet B. Enzymatic reactions envolved in repair of oxidized proteins. Exp Gerontology 2004; 39: 1117-1123.

Yao J, Reddy R, van Kammen D. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287-310.

Akyol Ö, Herken H, Uz E, Fadillio?lu E, Unal S, Sö?üt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog in Neuro-Psychoph and Biol Psychiatr 2002; 26: 995-1005.

Liou YJ, Lai IC, Lin MW, Bai YM, Lin CC, Liao DL, et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet and Genom 2006; 16: 151-157.

De Luca A, Sacchetta P, Di Ilio C, Favaloro B. Identification and analysis of the promoter region of the human methionine sulphoxide reductase A gene. Biochem J 2006; 393: 321-329.

Floyd R. Antioxidants, oxidative stress and degenerative neurological disorders. PSEBM 1999; 222: 236-245.

Hoffer A, Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1954; 100: 29-35.

Herken H, Uz E, Özyurt H, Sö?üt S, Virit O, Akyol Ö. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increase in different forms of schizophrenia. Molec Psychiatry 2001a; 6: 66-73.

Mahadik S, Mukherjee S, Scheffer R, Correnti E, Mahadik J. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998; 43: 674-679.

Herken H, Uz E, Özyurt H, Sö?üt S, Virit O, Akyol Ö. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001b; 52: 289-290.

Michel T, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 2004; 111: 1191-1201.

Yao J, Reddy R, van Kammen D. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000; 97: 137-151.

Yao J, Reddy R, van Kammen D. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80: 29-39.

Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990; 28: 959-966.

McCreadie R, McDonald E, Wiles D, Campbell G, Paterson J. The Nithsdale Schizophrenia Surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and normal subjects. Br J Psychiatry 1995; 167: 610-617.

Yao J, Reddy R, van Kammen D. Altered glutathione redox state in schizophrenia. Dis Mark 2006; 22: 83-93.

Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006; 79: 586-592.

Gysin R, Tosic M, Chappuis C, Deppen P, Ruiz V, Bovet P, et al. Dysregulation of glutamate cysteine ligase in schizophrenia. Paper presented at the 36th Annual Meeting of the Society of Neuroscience, Washington DC, November 12-16 2005.

Cavelier L, Jazin E, Eriksson I, Prince J, Bave U, Oreland L, et al. Decreased cytochrome c oxidase activity and lack of age related accumulation of mtDNA in brain of schizophrenics. Genomics 1995; 29: 217-228.

Karry R, Klein E, Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry 2004; 55: 676-684.

Akyol Ö, Yanik M, Elyas H, Namli M, Canatan H, Akin H, et al. Association between Ala-9Val polymorphism of Mn-Sod gene and schizophrenia. Progress in Neuro-Psychopharmacology and Biol Psychiatry 2005; 29: 123-131.

Shinkai T, De Luca V, Zai G, Shaikh S, Matsumoto C, Arnold P, et al. No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. Psychiatr Genet 2004; 14: 177-180.

Balderas T, Montero A, Benavides E, Rodríguez S, Almasy L, Raventós H, et al. Linkage disequilibrium analysis of schizophrenia in the Costa Rican population: preliminary findings on chromosome 18. Am J Med Genet 2001; 105: 599

Escamilla M, Raventos H, Almasy L, Montero P, Balderas T, Rodríguez S, et al. Linkage disequilibrium analysis of schizophrenia and schizoaffective disorder in the Costa Rican population: preliminary findings on chromosome 13. Am J Med Genet 2001; 105: 599.

Walss-Bass C, Escamilla MA, Raventós H, Montero A, Armas R, Dassori A, et al. Genome Wide linkage disequilibrium analysis of schizophrenia in the Costa Rican population: preliminary findings on chromosomes 1, 8, 13 y 22. Am J Med Genet 2002; 114: 877.

De Lisi L, Mesen A, Rodríguez C, Bertheau A, LaPrade B, Llach M, et al. Genome-wide scan for linkage to schizophrenia in a Spanishorigin cohort from Costa Rica. Am J Med Genet 2002; 114: 497-508.

Cooper-Casey K, Mésen-Fainardi A, Galke-Rollins B, Llach M, Laprade B, Rodríguez C, et al. Suggestive linkage of schizophrenia to 5p13 in Costa Rica. Molec Psychiatry 2005; 10: 651- 656.

Walss-Bass C, Escamilla MA, Raventós H, Montero A, Armas R, Dassori A, et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am J Med Genet 2005; 139: 54-60.

Walss-Bass C, Montero AP, Armas R, Dassori A, Contreras S, Liu W, et al. Linkage disequilibrium analices in the Costa Rican population suggests discrete gene loci for schizophrenia at 8p23.1 and 8q13.3. Psychiatr Genet 2006; 16: 159-168.

Moskovitz J, Jenkins N, Gilbert D, Copeland N, Jursky F, Weissbach H, et al. Chromosomal localization of the mammalian peptidemethionine sulfoxide reductase gene and its differential expression in various tissues. PNAS 1996; 93: 3205-3208.

Mowry B, Nacarrow D. Molecular genetics of schizophrenia. Clin Exp Pharmacol Physiol 2001; 28: 66-69.

Dawson E, Murray R. Schizophrenia: a gene at 6p? Curr Biol 1996; 6:

-271.

Descargas

Publicado

2008-10-30

Cómo citar

Soto Bernardini, M. C., & Raventós Vorst, H. (2008). Papel del estrés oxidativo en la esquizofrenia. Acta Médica Costarricense, 50(4), 197–202. https://doi.org/10.51481/amc.v50i4.3